[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 500
Citations 0
In This Issue of JAMA Psychiatry
February 2020

Highlights

JAMA Psychiatry. 2020;77(2):109. doi:10.1001/jamapsychiatry.2019.2784

Negative symptoms represent a substantial burden in schizophrenia without an available effective treatment. Valiengo and colleagues conducted a double-blind sham-controlled randomized clinical trial of add-on transcranial direct current stimulation for negative symptoms in 100 stable patients with schizophrenia and found that 10 sessions over the left prefrontal cortex over 5 days led to significantly greater improvement in negative symptom scores at weeks 6 and 12 when compared with the sham procedure. Thus, transcranial direct current stimulation is effective and safe in ameliorating negative symptoms in patients with schizophrenia.

Author Audio Interview

Stellate ganglion block treatment has been proposed but not adequately studied for treating posttraumatic stress disorder. Rae Olmsted and colleagues conducted a blinded sham-controlled randomized clinical trial with 113 active-duty service members with posttraumatic stress disorder symptoms and found that right-sided stellate ganglion block at weeks 0 and 2 was significantly more effective for reducing these symptoms from baseline to 8 weeks than sham procedure was. These findings indicate that stellate ganglion block merits further study as a posttraumatic stress disorder treatment.

×